Applications of 1,4,7,10-Tetraazacyclododecane Tetrahydrochloride in Industrial Manufacturing

As a direct producer of 1,4,7,10-Tetraazacyclododecane Tetrahydrochloride, we supply this macrocyclic ligand to specialized industrial sectors requiring high-purity chelating agents and complexing intermediates. Our material supports the production of next-generation diagnostics, advanced therapeutic agents, high-performance catalysts, and precision analytical components. We provide tailored grades to match downstream chemical processes and compliance frameworks across demanding applications.

1. Contrast Agent Precursor for Medical Imaging

Manufacturers use 1,4,7,10-Tetraazacyclododecane Tetrahydrochloride as a key intermediate in the synthesis of gadolinium and manganese-based contrast agents for magnetic resonance imaging. The macrocycle forms a stable complex, minimizing free metal ion release and enhancing patient safety. Downstream, this raw material must meet stringent pharmaceutical standards, and its composition significantly affects both chelation stability and kinetic inertness within the formulated injectable.

Industry compliance standards

• USP and EP monographs for MRI contrast ingredients
• 21 CFR Part 211 (GMP for finished pharmaceuticals)
• ICH Q7 guidelines for API manufacture
• REACH registration for pharmaceutical intermediates

Typical usage ratio

• 1.05–1.10 molar equivalents relative to metal ion in batch complexation, adjusted for stoichiometric purity and yield

Downstream process integration

• Charged as the principal macrocyclic chelator during metal acetate addition step
• pH-controlled process reactors ensure high-complexation efficiency

Final product types

• Gadolinium-DOTA contrast agents (e.g., Gadoteric acid injections)
• Manganese-based MRI contrast formulations
• Lyophilized imaging agent kits

2. Chelating Ligand for Radiopharmaceutical Synthesis

The material sees extensive use in nuclear medicine for preparing radiometal-labeled diagnostics and therapeutics, especially with isotopes such as In-111, Lu-177, and Y-90. Its macrocyclic structure provides robust coordination, critical for the stability and bio-distribution of finished radiopharmaceuticals. Users demand ultra-pure grades with reliably low metal contamination and batch-to-batch consistency as essential criteria for regulatory approval and patient safety.

Industry compliance standards

• Ph. Eur. monographs on radiopharmaceutical preparations
• cGMP certification for radiopharmaceutical intermediates (EU GMP Part I / Part II)
• ISO 13485 for medical devices (when integrated into kit manufacturing)
• ISO 9001:2015 for supplier quality assurance

Typical usage ratio

• 1:1 molar ratio with metal radionuclide; may increase by 5–10% for in-situ chelation kits

Downstream process integration

• Added in pre-formulated kit vials or loaded directly into reactor vessels under aseptic conditions
• Integrated into solid-phase or solution-based labeling protocols

Final product types

• Radiolabeled peptides (e.g., DOTATATE, DOTATOC analogs)
• Theranostic kits for NET imaging and therapy
• In-house radiopharmaceutical synthesis reagents

3. Homogeneous Catalysis in Organic Synthesis

In fine chemical and pharmaceutical synthesis, downstream users deploy this macrocyclic amine to construct transition metal complexes for homogeneous catalysis. These catalysts achieve site-selective activation, radical coupling, and cycloadditions in multi-step synthesis. Batch reproducibility and material traceability directly influence process reproducibility and end-use specification fulfillment.

Industry compliance standards

• ISO 9001 for chemical manufacturing
• Regulation (EC) No 1907/2006 (REACH) for registered downstream use
• US EPA TSCA Inventory listing for catalyst intermediates
• Safety Data Sheet (SDS) in line with GHS/CLP

Typical usage ratio

• 0.1–1.5 mol% relative to total reactant load, adjusted based on target conversion and specific substrate

Downstream process integration

• Used in solution or immobilized on polymer supports
• Initial catalyst complex forms in situ before substrate dosing

Final product types

• Active pharmaceutical ingredient (API) intermediates
• Agrochemical actives and fine chemicals
• Regioselective functionalized molecules

4. Ion-Selective Sensor Membrane Manufacturing

Producers of high-performance electrochemical sensors rely on this macrocycle to fabricate ion-selective electrodes and membrane sensors. Its selective complexation enables precise recognition of rare earth, alkali, and transition metal ions. Quality requirements call for high solubility, minimal residual free amine, and defined chloride content to avoid sensor drift and improve shelf stability.

Industry compliance standards

• IEC 60529 for sensor protection class
• RoHS Directive (2011/65/EU) for finished electronics
• ISO 9001 and calibration traceability according to ISO/IEC 17025
• Restriction of hazardous substances in sensor components

Typical usage ratio

• 20–80 mg per 10 g polymer membrane material, based on target ion selectivity and sensitivity curve

Downstream process integration

• Dissolved with plasticizer and PVC base in solvent casting process
• Directly coated onto conductive electrode surfaces and cured

Final product types

• Ion-selective electrodes (Na⁺, K⁺, Ca²⁺, rare earths)
• Membrane-type laboratory sensors for clinical diagnostics
• Industrial water quality monitoring probes